stockrowLivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.
- Revenue
- +9.88%
- EPS
- +27.4%
- Free cash flow
- −31.0%
- Total debt
- −31.2%
Quarter to September 2026, against a year earlier
Follow LIVN
Alert me
LivaNova PLC (LIVN) Return on equity
LivaNova PLC's return on equity over the twelve months to 30 September 2026 was 15.5%, up 34.7 percentage points from fiscal 2025 (−19.2%). Over the past ten years it has ranged from −28.0% (fiscal 2020) to 21.6% (fiscal 2015); the current reading is higher than 17% of that period. That is above the Medical Devices industry median of −10.4% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −19.2% | (24.11) |
| FY2024 | 4.87% | 3.46 |
| FY2023 | 1.41% | 8.30 |
| FY2022 | −6.89% | 4.41 |
| FY2021 | −11.3% | 16.68 |
| FY2020 | −28.0% | (17.06) |
| FY2019 | −10.9% | 0.49 |
| FY2018 | −11.4% | (9.99) |
| FY2017 | −1.42% | 2.15 |
| FY2016 | −3.57% | (3.57) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LIVN LivaNova PLC | 15.5% |
| BIO Bio-Rad Laboratories, Inc. compare | 14.3% |
| HAE Haemonetics Corporation compare | 11.9% |
| ITGR Integer Holdings Corporation compare | 5.97% |
| NEOG Neogen Corporation compare | −2.67% |
| BRKR Bruker Corporation compare | −7.04% |
| TXG 10x Genomics compare | −9.40% |
| AXGN AxoGen, Inc. compare | −10.4% |
| IRTC iRhythm Holdings, Inc. compare | −25.8% |
| Medical Devices industry median | −10.4% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on LIVN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement